Equities analysts predict that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post ($0.56) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.80). Dicerna Pharmaceuticals posted earnings of ($0.68) per share in the same quarter last year, which indicates a positive year over year growth rate of 17.6%. The business is scheduled to report its next quarterly earnings results on Thursday, March 29th.
Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Dicerna Pharmaceuticals.
Several research firms have recently issued reports on DRNA. Evercore ISI began coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 price objective on the stock. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Chardan Capital restated a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. Finally, BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $10.05.
A number of institutional investors have recently modified their holdings of DRNA. Northern Trust Corp boosted its holdings in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,094 shares during the last quarter. Endurant Capital Management LP acquired a new position in Dicerna Pharmaceuticals in the fourth quarter valued at $170,000. Birchview Capital LP boosted its holdings in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 25,000 shares during the last quarter. Emerald Advisers Inc. PA acquired a new position in Dicerna Pharmaceuticals in the fourth quarter valued at $266,000. Finally, EAM Investors LLC acquired a new position in Dicerna Pharmaceuticals in the fourth quarter valued at $581,000. Hedge funds and other institutional investors own 24.60% of the company’s stock.
Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) opened at $12.49 on Friday. Dicerna Pharmaceuticals has a fifty-two week low of $2.52 and a fifty-two week high of $12.53. The stock has a market capitalization of $674.15, a price-to-earnings ratio of -3.64 and a beta of 2.75.
TRADEMARK VIOLATION WARNING: This piece was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2018/02/24/dicerna-pharmaceuticals-inc-drna-expected-to-announce-earnings-of-0-56-per-share.html.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.